You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 翰森製藥(3692.HK)漲超7% 自研創新藥恆沐成功納入新醫保
格隆匯 12-09 15:56
格隆匯12月9日丨翰森製藥(3692.HK)漲7.29%,報18.24港元,總市值1080億港元。公司自主研發的1類新藥恆沐(艾米替諾福韋片)首次被納入醫保目錄。作為中國首個原研口服抗乙型肝炎病毒(HBV)藥物,恆沐於今年6月23日由NMPA批准正式上市。從上市到進入醫保,只用了短短5個月的時間。近年來,翰森製藥正穩步推進創新轉型戰略,在研藥物百餘個,20多個創新藥進入臨牀階段,創新藥正逐步成為公司的成長驅動主力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account